suritozole suritozole suritozole (mdl 26,479) is an investigational cognition enhancer. it acts as a partial inverse agonist at the benzodiazepine receptor site on the gabaa ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other bzd inverse agonists such as dmcm. it was investigated for the treatment of depression and alzheimer's disease, but clinical development seems to have been discontinued. suritozoleclinical dataatc codenoneidentifiers iupac name 5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3h-1,2,4-triazole-3-thione cas number110623-33-1 ypubchem cid25431chemspider23743 nunii3h7h68317xkeggd05980 ycomptox dashboard (epa)dtxsid10149333 chemical and physical dataformulac10h10fn3smolar mass223.27 g·mol−13d model (jsmol)interactive image smiles cn1c(=s)n(c)nc1-c2cccc(f)c2 inchi inchi=1s/c10h10fn3s/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6h,1-2h3 nkey:iwduzehnlhfbrz-uhfffaoysa-n n ny (what is this?) (verify) synthesis synthesis: ~85%: patents: etc the reaction between monomethylhydrazine (1) and methyl isothiocyanate (trapex) (2) gave 2,4-dimethylthiosemicarbazide (3). amide formation with 3-fluorobenzoyl chloride (4) yielded 1-(3-fluorobenzoyl)-2,4-dimethylthiosemicarbazide (5). cyclization to suritozole (6).